Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Brian Nicholson reacts to news that GPs in England will have direct access to book cancer tests for their patients

This initiative, announced by the NHS England Chief Executive, is part of the drive to diagnose cancers earlier in the NHS by “fast-tracking” community-based diagnostic testing.

Assessing a combined approach for risk-stratified population screening for colorectal cancer

Polygenic risk scores only modestly improve the predictive power of the QCancer-10 non-genetic risk score for colorectal cancer

Pancreatic cancer could be diagnosed up to three years earlier

Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.

OxCODE researchers at the Early Detection of Cancer Conference 2022

Oxford’s early detection research was featured at this annual event.

Funding boost for Oxford’s early cancer detection research in the NIHR Oxford BRC

The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive £86.6m over the next five years to fund 15 research themes.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Oxford Centre for Early Cancer Detection Symposium 2022 – a recap

On Tuesday 13th September, the Oxford early cancer detection community gathered at Worcester College to discuss the latest developments in this field, sparking ideas and collaborations for future research.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer at Oxford

Read about how Oxford's experts are leading the way in cancer prevention, detection and treatment as part of the University's Cancer at Oxford series

Unique clinical imaging dataset released for artificial intelligence research to accelerate diagnosis of prostate cancer

The National Cancer Imaging Translational Accelerator (NCITA) in partnership with the ReIMAGINE Consortium have announced the release of a unique clinical imaging dataset from the Prostate MRI Imaging Study (PROMIS)).

Funded DPhil studentships in early detection available - apply now for October 2023 entry

Oxford research groups are recruiting DPhil candidates for the funded DPhil in Cancer Science commencing in October 2023.

OxCODE travel awards 2022

Congratulations to Joshua Bull, Felix Jackson, Eoghan Mulholland and Lauren Murphy who have been awarded OxCODE funds to attend this year’s Early Detection of Cancer conference in Oregon.

CRUK funding to investigate the molecular drivers of stomach cancer

Dr Francesco Boccellato wins a CRUK Early Detection and Diagnosis primer award to study tissue shape changes in the pre-cancerous stomach conditions, atrophic gastritis and intestinal metaplasia

First patient diagnosed earlier using liquid biopsy technology as part of the AI-REAL programme in sub-Saharan Africa

The AI-REAL programme led by Professor Anna Schuh and research teams in Tanzania and Uganda is improving the early detection and outcomes of childhood lymphoma in the region by increasing the speed and precision of diagnosis.

Measured weight loss associates with an increased risk of a cancer diagnosis

Weight loss is a sign of undiagnosed cancer regardless of the interval over which it occurs.

Comparing polygenic risk scores for risk prediction in individuals

Substantial disagreement in individual risk prediction was found between different polygenic risk scores for breast cancer, hypertension and dementia using genotyping data from the UK Biobank.

Oxford research contributes to new guidelines on faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer

The joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) provides a clear strategy for the use of FIT in the colorectal cancer diagnostic pathway.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

OxCODE funding scheme awards 2022

Congratulations to Sarah Blagden, Skirmantas Kriaucionis and their collaborators who have been awarded funding in the third round of the OxCODE Funding Scheme.

Largest study to date confirms role of two hormones in aggressive prostate cancer risk

New, genetics and blood-based study links testosterone and insulin-like growth factor hormones to aggressive prostate cancer for the first time.

Load More